[Consensus statement: Stroke prevention in nonvalvular atrial fibrillation in special consideration of the new direct oral anticoagulants]

Wien Klin Wochenschr. 2014 Dec;126(23-24):792-808. doi: 10.1007/s00508-014-0586-5. Epub 2014 Oct 3.
[Article in German]

Abstract

The introduction of new direct oral anticoagulants has changed the treatment of nonvalvular atrial fibrillation. However, these changes are not yet fully reflected in current guidelines.This consensus statement, endorsed by six Austrian medical societies, provides guidance to current prophylactic approaches of thromboembolic events in nonvalvular atrial fibrillation on the basis of current evidence and published guidelines. Furthermore, some special subjects are treated, like changes in laboratory parameters and their interpretation under treatment with direct oral anticoagulants, treatment of bleedings, approach to operations, cardioversion and ablation, and specific neurological aspects. For a CHA2DS2-VASc-Score of ≥ 2, anticoagulation is recommended with a high level of evidence (1A). At the end of the consensus statement, recommendations for a number of specific patient subgroups can be found, in order to help treating physicians to arrive at appropriate therapeutic decisions.

Publication types

  • English Abstract

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage*
  • Atrial Fibrillation / complications*
  • Atrial Fibrillation / drug therapy*
  • Austria
  • Cardiology / standards*
  • Drug Administration Schedule
  • Evidence-Based Medicine
  • Heart Valve Diseases / complications
  • Heart Valve Diseases / therapy
  • Humans
  • Practice Guidelines as Topic
  • Stroke / etiology*
  • Stroke / prevention & control*

Substances

  • Anticoagulants